SALT LAKE CITY, May 9, 2018 /PRNewswire/ — Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that it has received a Complete Response Letter ("CRL") from the United States Food and Drug Administration ("FDA")…Original Article
Lipocine Receives Complete Response Letter for Tlando From U.S. Food and Drug Administration
